HCPCS J2782 is officially defined as "Injection, avacincaptad pegol, 0.1 mg." HCPCS J2782 is referenced in 5 tracked payer policy changes from Florida Blue, Blue Cross & Blue Shield of Mississippi, and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J2782 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Florida Blue is expanding their Physician-Administered Drug Program (PADP) effective March 1, 2026, requiring preservice reviews for 25 specific specialty drug codes before administration. Claims will be denied without prior authorization, and providers cannot bill patients for denied charges.
The policy update dated 11/01/2026 changes Vegzelma (bevacizumab-adcd) from non-covered to medically necessary when the listed indications are met. Alymsys (bevacizumab-maly), Beovu (brolucizumab), Cimerli (ranibizumab-eqrn), Eylea HD (aflibercept), Izervay (avacincaptad pegol), Susvimo (ranibizumab), Syfovre (pegcetacoplan) and Vabysmo (faricimab-svoa) are listed as not covered on the State Health Plan Medical Drug Formulary, and Avastin, Mvasi, Zirabev and Vegzelma are medically necessary for the listed neovascular (wet) AMD, diabetic macular edema, diabetic retinopathy, retinal vein occlusion macular edema and retinopathy of prematurity indications. Byooviz, Eylea, Lucentis and Pavblu may be considered medically necessary when the listed age, diagnosis, prior treatment and specialist criteria are met.
Vegzelma (bevacizumab-adcd) changed from non-covered to medically necessary when the listed indications are met, according to an update dated 11/01/2026. Avastin, Mvasi, Vegzelma and Zirabev are medically necessary for neovascular wet age-related macular degeneration, several other choroidal neovascularization causes, diabetic macular edema, diabetic retinopathy, macular edema after central or branch retinal vein occlusion, and retinopathy of prematurity. Byooviz, Eylea, Lucentis and Pavblu require prior authorization, while Alymsys, Beovu, Cimerli, Eylea HD, Izervay, Susvimo, Syfovre and Vabysmo are not covered on any BCBSMS Formulary.
Florida Blue Medicare updated its Part B Step Therapy program effective July 15, 2025, removing Erythropoiesis Stimulating Agents from step therapy requirements and adding new non-preferred drugs in Cancer/Supportive Therapy, Complement Inhibitors, and Ophthalmic Agents categories that will require step therapy through preferred alternatives first.
Premera HMO medical policies were revised effective April 1, 2024 for drugs including Padcev, Braftovi, Imbruvica, Jaypirca, generic gefitinib, Injectafer, Zelsuvmi and Vabysmo, and new policies made total facet arthroplasty for lumbar spinal stenosis and CO2 fractional laser ablation for hypertrophic scars and keloids investigational. Carelon Medical Benefits Management guideline updates for radiation therapy and advanced imaging apply to dates of service on and after April 14, 2024, and genetic testing updates apply to dates of service on and after June 30, 2024. Coding changes effective April 1, 2024 added codes that now require review for medical necessity, investigational status or prior authorization, moved Carelon Management Genetic Testing codes to Carelon review, and terminated codes including Q4244, C9160 and C9162.
Watch J2782
Get one email when a payer policy names J2782, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
See every payer rule for J2782
Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for J2782 in one place.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.